clinical trial · NCT01784536
Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers
Melinta Therapeutics, Inc.·phase1·completed·n = 16
HealthySingle-Dose IV Oritavancin Diphosphate
brief summary
The purpose of this study is to examine the effects of oritavancin on the in vivo activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT 2, and XO using a Cooperstown 5 + 1 cocktail in an open label, single arm manner.
started
Jan 1, 2013
primary completion
Mar 1, 2013
completion
Mar 1, 2013
last updated
Dec 19, 2023
official title
Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults Using the Cooperstown 5 + 1 Cocktail
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol